Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acurx Pharmaceuticals, Inc. - Common Stock (NQ:ACXP)

4.388 -0.382 (-8.01%)
Streaming Delayed Price Updated: 12:30 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Acurx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
New to The Street TV Commercial Campaigns Achieve Millions of Views with 87% Average Completion Rate
Via ACCESS Newswire
New to The Street Announces the Broadcast of Show Number 675 This Saturday at 6:30 PM EST on Bloomberg Television Featuring: FLOKI, BioVie (NASDAQ: BIVI), Arrive AI ($ARAI), Health In Tech (NASDAQ HIT), and Commercialville T.V.
Via ACCESS Newswire
Power Metallic (TSX.V: PNPN) Secures Largest Saudi License Amid June 2025 Gold Surge – Material Gains & More Stocks Inside
Via AB Newswire
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days
Via ACCESS Newswire
New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST
Via ACCESSWIRE
Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach
Via ACCESS Newswire
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice
Via ACCESS Newswire
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie’s Dr. Joe Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President
Via ACCESS Newswire
New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice
Via ACCESS Newswire
New to The Street & Sight & Sound's Visionaries Series Premieres Tomorrow on Bloomberg at 6:30 PM EST, Featuring Acurx Pharmaceuticals NASDAQ:ACXP
Via ACCESS Newswire
New to the Street to Broadcast Show 627 on Bloomberg Television at 6:30 PM EST Today as Sponsored Programming
Via ACCESS Newswire
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
Via ACCESSWIRE
New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tank's Kevin Harrington, Acurx Pharmaceuticals, the Sustainable Green Team, and SEKUR’s "Hack of the Week"
Via ACCESSWIRE
New to The Street on Fox Business Premieres Exclusive Sponsored Programming Tonight Featuring Modular Medical (NASDAQ:MODD), Acurx Pharmaceuticals (NASDAQ:ACXP), and LightPath Technologies (NASDAQ:LPTH)
Via ACCESSWIRE
Bloomberg’s “New to The Street” Segment by PetVivo Inc. (OTCQB: PETV) Stocks to Watch This Week inside….
Via AB Newswire
Topics Electric Vehicles
New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support
Via ACCESSWIRE
New to the Street Announces Exclusive Bloomberg Lineup for Saturday October 12 at 6:30 PM EST
Via ACCESSWIRE
New to the Street Announces Its Five Corporate Interviews, Airing Episode 599 on the Fox Business Network, Tonight Monday, September 9, 2024, at 10:30 PM PT September 9, 2024 09:15 ET
Via ACCESSWIRE
New to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNV
Via AB Newswire
Acurx Pharmaceuticals’ Phase 2b Results For Ibezapolstat Bests Standard Of Care Vancomycin To Treat C. Difficile ($ACXP)
Via AB Newswire
Acurx Pharmaceuticals Share Price And Volume Are Surging Ahead Of Phase 2b Trial Data Release ($ACXP)
Via AB Newswire
Topics Death
In The Queue: AcurX Pharmaceuticals Earnings…Here’s What Investors Need To Know Before Thursday ($ACXP)
Via AB Newswire
Race To The Cure: Here’s Why Acurx Pharmaceuticals Could Win The Battle To Treat C. difficile ($ACXP)
Via AB Newswire
Acurx Pharmaceuticals CEO Is Confident His Ibezapolstat Can Earn Front-Line Designation To Treat C. difficile…Here’s Why ($ACXP)
Via AB Newswire
Acurx Is Vying for Standard of Care in Treating Primary and Recurrent C. diff
C. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United... 
Via TheNewswire.com
Topics Death
Acurx Pharmaceuticals Surges 29% In August, Here’s Why The ACXP Bulls Expect Much More To Come ($ACXP)
Via AB Newswire
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
Via AB Newswire
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
Via AB Newswire
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
Via AB Newswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.